Nivolumab verslaat ipilimumab als adjuvante behandeling bij melanoom

Delen via:
ESMO 2017

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant therapy witz nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238). ESMO 2017 Congress; abstract LBA8_PR.,Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. DOI: 10.1056/NEJMoa1709030.

Longkankersymposium 2017

jan 2017 | Longoncologie

Lees meer over Longkankersymposium 2017